Switching From Tobramycin Inhalation Treatment to Tobramycin Inhaler Treatment: The Effect on CF Patients' Adherence and Quality of Life

Sheba Medical Center

Status: Unknown

Conditions: Alteration in Quality of Life of CF Patients, Following Change of Treatment From Antibiotic Inhalation to Antibiotic Inhaler

Study type: Observational

Funder types: Other

Identifiers

NCT01749644

SHEBA-12-9640-OE-CTIL

Details and patient eligibility

About

Pseudomonas is a common and virulent respiratory bacteria in patients with Cystic Fibrosis (CF). With time, the infection with Pseudomonas becomes chronic and very difficult to eradicate. The standard treatment of chronic Pseudomonas infection is inhaled Tobramycin which is given every other month.. Inhalation of Tobramycin was proven as an effective treatment that improves the respiratory function and reduces the concentration of bacteria in the sputum. However, inhaled treatment lasts between 15 to 30 minutes twice a day and therefore adherence is a major problem. The effect of switching from inhalation treatment to inhaler treatment on patient's adherence and quality of life has not been studied.

Enrollment: 40 estimated patients

Sex: All

Ages: 6+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 6 years and above, Chronic Pseudomonas infection

Exclusion criteria

• Younger than 6 years; No chronic PSeudomonas infection

Trial design

40 participants in 1 patient group

CF patients with chronic pseudomonas infection